Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: MoneyPenny who wrote (8251)	10/27/1999 12:22:00 PM
From: Nemer	Respond to of 9523

MP --- I've held Pfizer for a fairly good while and see no reason to do anything but continue in that pattern ..... but that does not mean that I don't pay attention to "changes in company operation" ..... Pfizer has never been much, (my personal opinion only), in the matter of catering to analysts, so I can discount some of the reporting facts from the article you posted ... but thanks for giving it to the thread ... I rarely read Motley Fool and would definitely have missed seeing it otherwise. I found it had some important things to say and consider .... and I don't mean to imply that an investor should ignore change in the way that ANY company does reporting, accounting, pr, etc ..... maybe this will help assuage the feeling of "hiding things" that the Fool created with their report .... From Pfizer's "Mission Watch" newsletter... From Hank McKinnell, Prez, Pfizer Pharmaceuticals Group As many of you know, Pfizer's long term goal is to be the number one prescription pharmaceutical company in the world by the year 2001. I'm pleased to report that we are well ahead of schedule. In fact, on a moving annual total (MAT) basis, it appears that we are now number one, according to preliminary IMS data through the first half of the year. Congratulations on this enormous accomplishment. But before we celebrate, remember that our goal is to be number one not for a day or a quarter, but for the full year, and then to stay there. So the mission watch continues. Note ------>>: MAT sales trends shows that sales for the period July 1, 1998 to June 30, 1999 Pfizer prescription sales were $11,945,000,000 AstraZeneca sales were $11,075,000,000 Merck's were $10,704,000,000. And this looks good, too .... Pfizer uses a tool to measure it's growth relative to that of the top 10 competitors. It's called the "MachMeter", and it measures revenue growth relative to AstraZeneca, Merck, Glaxo, Novartis, Bristol Myers, J&J, Lilly, American Home, and SmithKline. A reading of 100 means the company is growing at exactly the rate of the overall market. A reading of 95 means the company is growing at a rate 5% below that of the overall market, and a 105 would suggest revenue growth 5% above the overall market. Well, here is the breakdown... Pfizer: 115 Astra: 105 Merck: 97 Glaxo: 95 Novartis: 92 Bristol Myers: 105 J & J: 107 American Home: 95 SmithKline: 100 PPG (Pfizer Pharmaceutical Group) continued to deliver market-beating growth, dramatically outpacing the top 10 competitors. Strong MachMeter performance is driving PPG's emergence ahead of schedule as #1 in prescription pharmaceutical sales. Six month revenue breakdown for prescription drug sales: (Jan - June 1999) Pfizer Pharm Group: $7,115M (+24%) Norvasc: $1,425M (+20%) Zoloft: $988M (+15%) Alliance Revenue (Aricept, Celebrex, Lipitor): $883M (+154%) Zithromax: $648M (+38%) Viagra: $503M (+22%) Diflucan: $473M (+8%) Cardura: $382M (+16%) Zyrtec: $271M (+45%)